Application of Fex3 in preparation of medicine for resisting cholestatic liver injury

By developing aniline compounds such as Fex3, using their intestinal restriction characteristics and FXR agonist modification, the problem of no response rate and side effects of existing PBC treatment drugs was solved, significantly reducing the abnormal blood biochemical index of cholestatic liver injury and Liver fibrosis provides new therapeutic strategies.

CN118986948APending Publication Date: 2024-11-22CHINA PHARM UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411118732.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-15
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing drugs for treating primary biliary cirrhosis (PBC) such as UDCA have a 40% non-response rate, and combined administration of obebilic acid increases the risk of itching side effects, and there is a lack of effective small molecule drug solutions.

Method used

A aniline compound called Fex3 was developed, which is engineered by its intestinal restrictive features and FXR agonist modifications to prepare anticholestatic liver injury drugs, reducing liver fibrosis and inflammation, and reducing peripheral side effects.

Benefits of technology

Fex3 significantly reduces abnormal blood biochemical indicators caused by cholestasis, reduces liver fibrosis and inflammation, and provides a new potential strategy for the treatment of PBC and reduces the risk of side effects of drug combination.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118986948A_ABST
    Figure CN118986948A_ABST
Patent Text Reader

Abstract

The invention discloses application of Fex3 in preparation of a medicine for resisting cholestatic liver injury. The Fex3 can be used as an active ingredient and is applied to treatment of cholestatic liver injury, new application of the Fex3 is developed, and a new choice is provided for preparation of the medicine for treating cholestatic liver injury. The Fex3 disclosed by the invention does not enter blood circulation due to the characteristic of intestinal tract limitation, so that peripheral side effects can be reduced while a treatment effect is exerted. Therefore, Fex3 can be used for preparing the medicine for resisting cholestatic liver injury.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medical technology, and specifically relates to an application of Fex3 in the preparation of an anti-cholestatic liver injury drug. Background Art

[0002] Cholestatic liver injury is a common clinical phenomenon. Cholestasis may occur inside or outside the liver. Intrahepatic bile formation and excretion disorders or extrahepatic bile duct obstruction can lead to cholestasis.

[0003] Primary Biliary Cirrhosis (PBC) is a chronic intrahepatic cholestatic disease and an autoimmune liver disease. Serum antimitochondrial antibodies (AMA) are specific indicators for the diagnosis of PBC, and ursodeoxycholic acid (UDCA) is the only drug proven safe and effective for the treatment of PBC by randomized controlled clinical trials. Although the pathogenesis of PBC may be related to autoimmunity, the efficacy of immunosuppressants has not been proven, and drug-related adverse reactions limit their clinical application.

[0004] Currently, UDCA, one of the first-line drugs for the treatment of PBC patients, is a regulator that can bind to FXR, but 40% of patients still do not respond to it, and the introduction of co-administration of obeticholic acid (OCA) increases the risk of itching side effects. Therefore, it is necessary to develop small molecule drugs for the treatment of PBC.

[0005] Fex3 is derived from the FXR agonist Fexeramine and can be used to treat metabolic diseases such as obesity. Currently, there are no reports on its use in the treatment of cholestatic liver injury. Summary of the invention

[0006] Purpose of the invention: The purpose of the present invention is to provide an application of Fex3 in the preparation of anti-cholestatic liver injury drugs. The present invention found that Fex3 significantly reduced the abnormal blood biochemical indicators caused by cholestatic liver injury, reduced liver fibrosis and inflammation; at the same time, Fex3 reduced peripheral side effects through its intestinal restrictive characteristics, providing new candidate compounds and potential treatment strategies for the treatment of PBC. Therefore, Fex3 can be used to prepare anti-cholestatic liver injury drugs.

[0007] Technical solution: The purpose of the present invention is achieved through the following technical solution:

[0008] The present invention provides an application of Fex3 in the preparation of an anti-cholestatic liver injury drug, wherein the structural formula of the Fex3 is as follows:

[0009]

[0010] Fex-3(methyl(E)-3-(3-(N-((4′-(dimethylamino)-[1,1′-biphenyl]-4-yl)

[0011] methyl)-6-(methylamino)-2-naphthamido)phenyl)acrylate)(C 37 H 35 N3O3, MW569.70) is a synthetic aniline compound.

[0012] The Fex3 is used as the sole active ingredient to prepare an anti-cholestatic liver injury drug.

[0013] The Fex3 is used in combination with other drugs to prepare anti-cholestatic liver injury drugs.

[0014] The Fex3 reduces peripheral side effects through its intestinal restrictive characteristics.

[0015] The Fex3 significantly reduces abnormal blood biochemical indexes caused by cholestatic liver damage.

[0016] The Fex3 significantly reduced liver fibrosis and inflammation.

[0017] The drug includes Fex3 and a pharmaceutically acceptable carrier or excipient.

[0018] The auxiliary materials include one or more of emulsifiers, wetting agents, diluents, antioxidants, preservatives, disintegrants or adhesives.

[0019] The emulsifier is selected from at least one of Tweens, Spans, glycerol fatty acid esters, pectin, agar, sodium alginate or silicon dioxide.

[0020] The wetting agent is selected from at least one of water and ethanol.

[0021] The diluent is selected from at least one of starch, sugar, cellulose or inorganic salts.

[0022] The antioxidant is selected from at least one of ascorbic acid, sulfite, bisulfite, gallic acid and lipids thereof.

[0023] The preservative is selected from at least one of benzoic acid and its salts, sorbic acid and its salts or parabens.

[0024] The disintegrant is selected from at least one of starch, sodium carboxymethyl starch, cross-linked polyvinyl pyrrolidone, low-substituted hydroxypropyl cellulose or cross-linked polyvinyl pyrrolidone.

[0025] The binder is selected from at least one of starch slurry, sodium carboxymethyl cellulose, povidone, hydroxypropyl cellulose, methyl cellulose or ethyl cellulose.

[0026] The dosage form of the medicine is granules, tablets, capsules, suspensions, oral liquids, injections or pills.

[0027] The effective dose of Fex3 is 20 mg / kg.

[0028] The drug of the present invention can be administered in various known ways, such as oral administration, injection, etc. The drug of the present invention can be administered alone or in combination with other drugs. The oral composition can be in any oral acceptable dosage form, including but not limited to granules, tablets, capsules, suspensions, solutions and dripping pills.

[0029] Sterile injectable compositions can be formulated according to techniques known in the art using suitable dispersants or wetting agents and suspending agents. Pharmaceutically acceptable carriers and solvents that can be used include water, sodium chloride solution, and the like.

[0030] The drug of the present invention can be made into common preparations, and can also be made into sustained-release preparations, controlled-release preparations, targeted preparations and various microparticle drug delivery systems.

[0031] The actual dosage level of the active ingredient in the medicament of the present invention can be varied to obtain an amount of active ingredient that is effective to achieve the desired therapeutic response and is non-toxic to the patient for a particular patient, composition, and mode of administration. The selected dosage level depends on a variety of factors, including the route of administration, time of administration, rate of excretion, duration of treatment, other drugs, compounds, and / or materials used in combination with Fex3, age, sex, weight, general health, and past medical history of the patient being treated, and similar factors known in the medical field.

[0032] The experimental study of the present invention found that Fex3 can significantly reduce the abnormal blood biochemical indicators caused by cholestatic liver damage. After five consecutive days of administration, the 20 mg / kg administration group can significantly reduce the increase in serum ALT and AST levels compared with the BDL model group. This indicator is an important indicator for evaluating liver damage. At the same time, by detecting the expression levels of liver fibrosis and inflammation-related genes mRNA (Col1a1, Col1a2, Col3a1, Timp1, Timp2, Tgfb, Acta2, Il6, Il1b, Tnfa), it can be seen that Fex3 can significantly reduce liver fibrosis and inflammation caused by BDL. In the ANIT chemical-induced liver injury model, Fex3 can also reduce related abnormal indicators under pathological conditions. The experimental results of the present invention suggest that Fex3 has a certain effect on anti-cholestatic liver damage.

[0033] Beneficial effects:

[0034] The Fex3 of the present invention can be used as an active ingredient and applied to the treatment of cholestatic liver injury, which opens up a new use of Fex3 and provides a new option for the preparation of drugs for the treatment of cholestatic liver injury. Due to its intestinal restrictive characteristics, the Fex3 of the present invention does not enter the blood circulation, and can reduce peripheral side effects while exerting a therapeutic effect. Therefore, Fex3 can be used to prepare drugs for anti-cholestatic liver injury. BRIEF DESCRIPTION OF THE DRAWINGS

[0035] Figure 1 This is the effect of compound Fex3 on the changes of blood biochemical indicators in mice caused by the BDL model.

[0036] Figure 2 This is the effect of compound Fex3 on fibrosis and changes in inflammatory-related factors in mice caused by the BDL model.

[0037] Figure 3 This is the effect of compound Fex3 on the changes of blood biochemical indicators in mice induced by ANIT.

[0038] Figure 4 This is the effect of compound Fex3 on ANIT-induced fibrosis and changes in inflammatory-related factors in mice.

[0039] Figure 5 This is a liver pathological section of ANIT-induced model mice.

[0040] Figure 6 This is a liver pathological section of BDL model mice. DETAILED DESCRIPTION

[0041] The technical solution of the present invention is described in detail below through specific embodiments, but the protection scope of the present invention is not limited to the embodiments.

[0042] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.

[0043] The experimental methods in the following examples are conventional methods unless otherwise specified. The experimental materials used in the following examples are commercially available products unless otherwise specified.

[0044] Fex3 purity ≥98%.

[0045] Example 1 Establishment of BDL model mice

[0046] 1. Solution preparation:

[0047] (1) Control solution: 300 μL of DMSO and 300 μL of Tween 80 were placed in a 5 mL centrifuge tube, vortexed to mix, and then 2400 μL of 0.5% CMC-Na solution was added and vortexed to form a stable suspension.

[0048] (2) 2 mg / mL (20 mg / kg) Fex3 suspension: Use a Sartorius 1 / 100,000 electronic balance to accurately weigh 6.00 mg of Fex3 powder into a 5 mL centrifuge tube, add 300 μL of DMSO and vortex to completely dissolve it, then add 300 μL of Tween 80 and vortex to mix, and finally add 2400 μL of 0.5% CMC-Na solution and vortex to form a stable suspension.

[0049] 2. Experimental Animals

[0050] C57BL / 6J male mice, 7 weeks old, weighing 19±1g, were purchased from Shanghai Slake Laboratory Animal Co., Ltd., SPF grade.

[0051] The mice were raised in a well-ventilated SPF environment at a temperature of 22±2℃, a humidity of 55±10%, with 12h of light and 12h of darkness, and free access to water and diet. They were divided into Sham group, BDL group, and BDL+20Fex3 group according to random double-blind selection, of which the Sham group was a sham operation group, the BDL group was a bile duct ligation group, and the BDL+20Fex3 group was a 20mg / kg Fex3 group. The mice were anesthetized with Avertin (100μL / 10g), and then the mice were depilated from the tip to the middle of the abdomen with depilatory cream, the abdomen was cut open, the bile duct was found, and it was ligated with non-absorbable sutures, and the abdomen was re-sutured. The mice in the Sham group only had the common bile duct freed, but not ligated, and other operations were consistent with the mice in the surgery group.

[0052] 3. Dosage method:

[0053] The drug was administered by intragastric gavage starting on the third day after surgery, once a day, and after the ninth day (a total of 7 days), the patient was fasted but not watered for 12 hours.

[0054] Example 2 Establishment of α-analool isothiocyanate (ANIT)-induced cholestasis model in mice

[0055] 1. Preparation of solution:

[0056] The preparation method of Fex3 solution is the same as that in Example 1.

[0057] Preparation of 7.5mg / ml ANIT: Accurately weigh 52.5mg ANIT powder and add 7ml edible oil and mix well.

[0058] Preparation of blank modeling solution: Edible oil was used as the blank modeling solution.

[0059] 2. Experimental Animals

[0060] C57BL / 6J male mice, 7 weeks old, weighing 19±1g, were purchased from Shanghai Slake Laboratory Animal Co., Ltd., SPF grade.

[0061] The mice were kept in a well-ventilated SPF environment at 22±2℃, 55±10% humidity, 12h light, 12h dark, and free access to water and food. They were randomly divided into Ctrl group, ANIT group, and ANIT+20Fex3 group by double-blind selection.

[0062] ANIT modeling: Each mouse was orally administered ANIT for 48 hours to establish the model.

[0063] Administration: Pre-administer Fex3 for five days, then orally administer 75 mg / kg ANIT on the fifth day, and gavage 200 μL ANIT for every 20 g of body weight. Continue administering Fex3 for two days. The dosage is 20 mg / kg; the administration route is oral administration. Example 3 Effects of Fex3 on changes in blood biochemical indicators caused by BDL model mice and ANIT model mice

[0064] Serum from BDL model mice and ANIT model mice was collected for subsequent experiments.

[0065] 1. Experimental methods:

[0066] The mouse serum was centrifuged at 8000 rpm for 10 min and the supernatant was taken. The ALT, AST, TBIL, ALP and TBA kits of Nanjing Jiancheng Bioengineering Institute were used to detect various indicators.

[0067] 2. Experimental results:

[0068] Fex3 improves BDL-induced liver damage: Figure 1 It can be seen that the levels of ALT and AST in serum will increase significantly under liver damage. Compared with the Sham group, the levels of ALT and AST in the serum of mice in the BDL group increased significantly by more than 10 times, indicating that the liver function of mice was abnormal. Compared with the BDL group, oral administration of Fex3 (20 mg / kg) can significantly reduce the increase in ALT and AST levels in serum caused by BDL, proving that the drug can improve cholestatic liver damage caused by BDL.

[0069] ANIT model: Figure 3It can be seen that compared with the Ctrl group, the levels of ALT and AST in the serum of mice in the ANIT group were significantly increased by more than 10 times, indicating that the liver function of the mice was abnormal; compared with the ANIT group, oral administration of Fex3 (20 mg / kg) reduced the increase in ALT and AST levels in the serum caused by ANIT, proving that the drug can improve ANIT-induced cholestatic liver damage.

[0070] Example 4 Effects of Fex3 on liver fibrosis and inflammatory changes caused by BDL model mice and ANIT model mice

[0071] 1. Sample processing:

[0072] 1. RNA extraction: Accurately weigh about 30 mg of liver lobes from BDL model mice and ANIT model mice, place in a homogenate tube, add 2 3 mm and 1 4 mm grinding beads, add 1 mL of RNAisoPlus (Trizol), use a tissue freezing grinder at 50 Hz, 45 s run, 15 s stop, -4 ° C to grind the liver 4 times, after grinding, use a 1 mL pipette to transfer it to a new 1.5 centrifuge tube, use a centrifuge at 13000g, 4 ° C, centrifuge for 10 min; after the end, aspirate 800 μL of the supernatant and transfer it to a new 1.5 centrifuge tube, add 160 μL of chloroform with 1 / 5 volume of Trizol, shake vigorously for 1 min, let it stand for 5 min; 13000g, 4 ° C, centrifuge for 15 min; aspirate 200 μL of the supernatant, add an equal volume of 200 μL of pre-prepared Add cold isopropanol and mix gently, place in a -20℃ refrigerator to precipitate RNA for 20 minutes, then centrifuge at 13000g, 4℃ for 10 minutes; discard the supernatant, add 1mL of 75% pre-cooled ethanol (DEPC water), shake the centrifuge tube up and down for 1.5 minutes to make the RNA precipitate float up and down for RNA washing; finally centrifuge at 13000g, 4℃ for 10 minutes, discard the supernatant, wait for ethanol to evaporate and RNA to air-dry to translucent, add appropriate amount of DEPC water, and use Nano to quantify RNA.

[0073] 2. Reverse transcription of total RNA: The entire process was carried out according to the instructions of the Novozymes RNA reverse transcription kit. All operations were performed on ice as follows:

[0074] Genome removal: template RNA 1μg, 4×gDNA wiper mix 4μL, RNase free H2O to 16μL, use a pipette to mix, and then perform genome removal at 42℃2min→4℃∞;

[0075] Reverse transcription system: Add 4 μL of 5×HiScriptⅢqRT SuperMix to the above mixed system and perform reverse transcription at 37℃15min→85℃5s→4℃∞. cDNA can be obtained as described above, and cDNA can be stored at -20℃ for 6 months and at -80℃ for a long time.

[0076] 3. RT-qPCR: The operation was strictly carried out in accordance with the instructions of the Novozymes RT-qPCR kit. The entire operation process was carried out on ice. The specific operations are as follows:

[0077] Preparation of qPCR system: ChamQ SYBR qPCR Master Mix, 7.5 μL; Primer-Forward (10 μM), 1 μL; Primer-Reverse (10 μM), 1 μL; cDNA 1 μL; DEPC water, 4.5 μL; a total of 15 μL.

[0078] The qPCR reaction conditions are shown in Table 1:

[0079] Table 1 Reaction conditions

[0080]

[0081] The primer sequence information is as follows:

[0082] Gapdh:

[0083] Forward primer (5'-3'): GAGAAACCTGCCAAGTATATGATGAC Reverse primer (5'-3'): TAGCCGTATTCATTGTCATACCAG Il6:

[0084] Forward primer (5'-3'): TAGTCCTTCCTACCCCAATTTCC Reverse primer (5'-3'): TTGGTCCTTAGCCACTCCTTC Il1b:

[0085] Forward primer (5'-3'): GCAACTGTTCCTGAACTCAACT Reverse primer (5'-3'): ATCTTTTGGGGTCCGTCAACT Tnfa:

[0086] Forward primer (5'-3'): CCTGTAGCCCACGTCGTAG

[0087] Reverse primer (5'-3'): GGGAGTAGACAAGGTACAAC Col1a1:

[0088] Forward primer (5'-3'): TAGGCCATTGTGTATGCAGC

[0089] Reverse primer (5'-3'): ACATGTTCAGCTTTGTGGACC Col1a2:

[0090] Forward primer (5'-3'): GCAGGGTTCCAACGATGTTG

[0091] Reverse primer (5'-3'): GCAGCCATCGACTAGGACAGA Col3a1:

[0092] Forward primer (5'-3'): GACCAAAAGGTGATGCTGGACAG Reverse primer (5'-3'): CAAGACCTCGTGCTCCAGTTAG

[0093] Timp1:

[0094] Forward primer (5'-3'): CATGGAAAGCCTCTGTGGATATG

[0095] Reverse primer (5'-3'): GATGTGCAAATTTCCGTTCCTT

[0096] Timp2:

[0097] Forward primer (5'-3'): ATGGTTCTTGCGCGTGGTA

[0098] Reverse primer (5'-3'): GCTTTTCAATTGGCCACAGG

[0099] Tgfb:

[0100] Forward primer (5'-3'): AGGAGACGGAATACAGGGCT

[0101] Reverse primer (5'-3'): CCACGTAGTAGACGATGGGC

[0102] Acta2:

[0103] Forward primer (5'-3'): GCACCCAGCATGAAGATCAAG

[0104] Reverse primer (5'-3'): TCTGCTGGAAGGTAGACAGCGAAG

[0105] The above primers were purchased from Bio-Tech.

[0106] 4. Animal histopathological examination: H&E staining, Masson staining, Sirius red staining and immunofluorescence staining (single label) of liver tissue were commissioned to Wuhan Saiweier Biotechnology Co., Ltd. The liver histopathological characteristics of mice in each group were observed.

[0107] 2. Experimental results:

[0108] 1. BDL model: Figure 2 It can be seen that compared with the Sham group, the mRNA levels of liver fibrosis-related genes (Col1a1, Col1a2, Col3a1, Timp1, Timp2, Tgfb and Acta2) and inflammation-related genes (Il6, Il1b, and Tnfa) in the BDL group were significantly increased. Compared with the BDL group, the administration of Fex3 (20 mg / kg) can significantly reduce the increase in the mRNA levels of liver fibrosis-related and inflammation-related genes caused by BDL.

[0109] 2. ANIT model: Figure 4 It can be seen that compared with the Ctrl group, the mRNA levels of liver fibrosis-related genes and inflammation-related genes in the ANIT group were significantly increased; compared with the ANIT group, the administration of Fex3 (20 mg / kg) can significantly reduce the increase in the mRNA levels of liver fibrosis-related genes and inflammation-related genes caused by ANIT.

[0110] 3. Pathological sections:

[0111] BDL model: Figure 6 It can be seen that compared with the BDL group, the fibrosis area caused by BDL increased after the administration of Fex3 (20 mg / kg), and the overall liver cavitation and collagen fibrin levels were significantly alleviated.

[0112] ANIT model: Figure 5 It can be seen that, like the sections of the BDL group, the fibrosis caused by ANIT was alleviated after drug administration.

[0113] Note: In the pathological sections, Scale bar = 50 μm. ns: P﹥0.05, **P﹤0.01, ***P﹤0.001.

[0114] As described above, although the present invention has been shown and described with reference to specific preferred embodiments, it should not be construed as limiting the present invention itself. Various changes in form and details may be made without departing from the spirit and scope of the present invention as defined in the appended claims.

Claims

1. The use of Fex3 in the preparation of an anti-cholestatic liver injury drug, characterized in that: The structural formula of the Fex3 is as follows:

2. The use according to claim 1, characterized in that: The Fex3 is used as the sole active ingredient to prepare an anti-cholestatic liver injury drug.

3. The use according to claim 1, characterized in that: The Fex3 is used in combination with other drugs to prepare anti-cholestatic liver injury drugs.

4. The use according to claim 1, characterized in that: The Fex3 reduces peripheral side effects through its intestinal restrictive characteristics.

5. The use according to claim 1, characterized in that: The Fex3 significantly reduces abnormal blood biochemical indexes caused by cholestatic liver damage.

6. The use according to claim 1, characterized in that: The Fex3 significantly reduced liver fibrosis and inflammation.

7. The use according to any one of claims 1 to 3, characterized in that: The drug includes Fex3 and a pharmaceutically acceptable carrier or excipient.

8. The use according to any one of claims 1 to 3, characterized in that: The dosage form of the medicine is granules, tablets, capsules, suspensions, oral liquids, injections or pills.

9. The use according to any one of claims 1 to 3, characterized in that: The effective dose of Fex3 is 20 mg / kg.